Gene Transfer Trial of scAAV9.U1a.hSGSH for Treating Mucopolysaccharidosis IIIA in Children
Led by Ultragenyx Pharmaceutical Inc · Updated on 2026-09-22
36
Participants Needed
5
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of UX111 for treating Mucopolysaccharidosis IIIA MPS IIIA, a rare genetic condition. This open-label trial tests a single intravenous dose of a gene therapy called scAAV9.U1a.hSGSH. The study includes a dose-escalation design where participants receive varying doses of UX111 to assess response and safety. Some participants may also receive immunomodulatory therapy to support treatment, decided by investigators and caregivers.
UX111 is administered once through a vein in a limb. The study involves up to four dosage groups, with doses ranging from 0.5 x 1013 to 3 x 1013 vector genomes per kilogram. Prophylactic immunomodulatory treatment is provided to all participants, with optional additional immunomodulatory therapy at certain sites depending on individual patient needs. This trial is conducted across multiple global locations and includes children from birth up to 5 years old, depending on the cohort.
Participants will undergo regular assessments including neurological development tests like the Bayley Scales of Infant and Toddler Development, and laboratory tests measuring cerebrospinal fluid substances related to the disease. Researchers will monitor changes in brain volume and enzyme activity over 24 months. Safety and immune responses will be closely followed. The total study duration extends up to 24 months after treatment, with ongoing evaluations to understand the long-term effects of the gene therapy.
CONDITIONS
Brief Title
Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSH
Research Team
P
Patients Contact: Trial Recruitment
H
HCPs Contact: Medical Information
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
UX111 Gene Therapy
Supportive Care
What it is
A single intravenous administration of a self‑complementary AAV9 vector carrying human SGSH under U1a promoter (UX111), given once with optional immunomodulation
Ongoing multidisciplinary supportive management focused on symptom treatment and complication prevention
Role in the study
Investigational therapeutic regimen delivered sequentially across dose cohorts
Not part of trial arms; reflects routine clinical management outside the trial
Primary use
Assess safety, tolerability, biomarkers, and developmental outcomes after gene transfer in MPS IIIA
Manage symptoms and support development through multidisciplinary interventions
How it is given or performed
One-time infusion via peripheral limb venous catheter plus immunomodulatory drugs as needed
Supportive therapies delivered as needed by clinicians in routine care
Evidence status
Early‑stage study; biomarker and developmental data are being collected but clinical effectiveness not yet established
Supportive care improves symptom management and quality of life but does not alter disease progression
Important risks
Risks associated with gene transfer and immunomodulatory therapy are under evaluation
Risks vary by supportive intervention and are managed as part of clinical care
Important limitations
Single‑arm design without randomized comparison limits ability to demonstrate causality
Supportive care cannot slow neurocognitive decline; does not modify disease course
Patient impact
Currently unknown; trial is collecting biomarker and developmental outcomes
Helps manage symptoms and maintain quality of life but does not prevent disease progression
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
All Ages
All Genders
Eligibility Criteria
You may qualify if you...
Diagnosis of MPS IIIA confirmed by no or reduced SGSH enzyme activity and genetic testing showing mutations in the SGSH gene
Age from birth (USA and Australia) or 6 months (Spain) to 2 years old with no cognitive score requirement, or older than 2 years with a cognitive development quotient of 60 or higher
For Cohort 4 (Spain): 3 months to 2 years old with no cognitive score requirement, or over 2 years with cognitive quotient 60 or above; up to 2 children aged 2 to 5 years with cognitive quotient below 60 may be enrolled
Participants must be at least 6 months old before receiving UX111
Vaccination status up to date 30 days before enrollment for Cohort 4, with willingness to defer vaccines after immunomodulatory treatment
You will not qualify if you...
Unable to participate in clinical evaluation as determined by investigator
For Cohorts 1 to 3: Having two nonsense or null SGSH gene variants
Presence of at least one S298P mutation in SGSH gene
Evidence of attenuated MPS IIIA phenotype
Medical conditions preventing lumbar puncture or anesthetic use
Active viral infections
Illness or treatments that increase gene therapy risks or prevent study procedures
For Cohorts 1 to 3: Positive anti-AAV9 antibodies or T-cell responses to AAV9
Exposure to HIV, active hepatitis B or C infection; for Cohort 4: clinically significant infections including HIV, hepatitis, tuberculosis, or COVID-19
Bleeding disorders or contraindications to lumbar puncture or MRI
Significant impairments preventing cooperation with testing
Uncontrolled seizure disorder
Cardiomyopathy or major congenital heart defects
Significant non-MPS IIIA CNS or behavioral problems affecting study results
For Cohorts 1 to 3: Abnormal lab values Grade 2 or higher in liver, kidney, blood, or clotting tests; for Cohort 4: similar lab abnormalities including anemia, leukopenia, coagulopathy, or renal impairment
Females who are pregnant or test positive for pregnancy
Recent vaccination with live viruses less than 30 days before treatment
Previous hematopoietic stem cell transplantation or gene/cell therapy or enzyme replacement trials
For Cohort 4: Known hypersensitivity increasing risk or unwillingness to avoid certain medications and grapefruit juice from 30 days before screening through immunomodulatory treatment completion
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 screening visit
Treatment
Duration - One-time treatment with follow-up for 24 months
Participants receive a single intravenous dose of the gene therapy UX111 along with a course of prophylactic immunomodulatory therapy. Additional immunomodulatory treatment may be given based on individual needs.
Regular follow-up visits up to Month 24
Follow-up
Duration - Up to 24 months after treatment
Participants undergo ongoing assessments including neurological evaluations, cerebrospinal fluid analysis, and imaging to monitor treatment effects and safety over 24 months.
Multiple scheduled visits during follow-up period
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
4
Similar Trials
Study of Mucopolysaccharidosis Patients in France to Understand Disease Progress and Treatment Effects
Gene Transfer Trial of scAAV9.U1a.hSGSH for Treating Mucopolysaccharidosis IIIA in Children
Randomized Placebo-Controlled Crossover Study of Oral Cannabidiol Epidiolex to Assess Neurobehavioral and Functional Effects in Children with Sanfilippo Syndrome
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Differential Prevalence of Antibodies Against Adeno-Associated Virus in Healthy Children and Patients with Mucopolysaccharidosis III: Perspective for AAV-Mediated Gene Therapy.